SARS-COV-2 Nucleocapsid (B.1.1.529/Omicron) protein (Recombinant) (C-His) (STJP001478)
SPECIFICATIONS
HostE.coli
ConjugationUnconjugated
ImmunogenRecombinant SARS-COV-2 Nucleocapsid (B.1.1.529/Omicron) Protein is produced by E. coli expression system. The target protein is expressed with sequence (Ser2-Ala419 (P13L, E31del, R32del, S33del, R203K, G204R) ) of sars-cov-2 N (B.1.1.529/Omicron) (A
General Information
| Short Description | Recombinant-SARS-COV-2 Nucleocapsid (B.1.1.529/Omicron)-C-His protein was developed in e.coli using the region Ser2-Ala419. For use in research applications. |
| Host | E.coli |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Conjugation | Unconjugated |
| Formulation | Supplied as a 0.22 Mu m filtered solution in 20mM Tris, 500mM NaCl, 0.1mM EDTA, 10% Glycerol, pH 8.0. |
| Storage Instruction | Store at-20ยฐC for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Immunoreactivity | Measured by its binding ability in a functional ELISA.Immobilized SARS-CoV-2 Envelope at 2 Mu g/mL (100 Mu L/well) can bind SARS-COV-2 Nucleocapsid with a linear range of 0.2-65 ng/mL. |
| Determination Method | <0.1 EU/Mu g |
Target Information
| Immunogen | Recombinant SARS-COV-2 Nucleocapsid (B.1.1.529/Omicron) Protein is produced by E. coli expression system. The target protein is expressed with sequence (Ser2-Ala419 (P13L, E31del, R32del, S33del, R203K, G204R) ) of sars-cov-2 N (B.1.1.529/Omicron) (A |
| Immunogen Region | Ser2-Ala419 |
| Immunogen Sequence | SDNGPQNQRNALRITFGGPS DSTGSNQNGGARSKQRRPQG LPNNTASWFTALTQHGKEDL KFPRGQGVPINTNSSPDDQI GYYRRATRRIRGGDGKMKDL SPRWYFYYLGTGPEAGLPYG ANKDGIIWVATEGALNTPKD HIGTRNPANNAAIVLQLPQG TTLPKGFYAEGSRGGSQASS RSSSRSRNSSRNSTPGSSKR TSPARMAGNGGDAALALLLL DRLNQLESKMSGKGQQQQG |